On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

MIDS Cardiac by Zenosense, Inc. (ZENO): A Heart Attack Diagnostic Revolution?

  • The handheld testing device technology under development by Zenosense aims to deliver rapid results and state-of-the-art, laboratory-accurate results for the quick diagnosis of heart attacks
  • Medical professionals believe that diagnosis within 30 minutes of a heart attack is the golden standard for ensuring adequate treatment
  • Cardiac diagnostic testing market estimated between $2 billion and $6 billion in the U.S. alone

MIDS Cardiac™, a handheld diagnostic device for cardiac emergency triage being developed by Zenosense, Inc. (OTCQB: ZENO), could prove to be revolutionary in the diagnostic process. Incorporating the patented MIDS technology, which is predicated on the nano-magnetic detection of assay beads and has demonstrated detection of low enough assay bead numbers to be suitable for high sensitivity cardiac biomarker tests, shows real potential to be able to ensure accurate results, delivered at a fraction of the time required by large and expensive laboratory analyzers and right at the point of care, according to an article by Zacks Small Cap Research (http://nnw.fm/u0w7A) and recent quantitative results released by Zenosense.

The device technology is being created via a partnership between Zenosense and a third-party medical detection device developer. The joint venture carries the name MIDS Medical, and it was set up in the summer of 2016. Zenosense has 40 percent interest in the venture that is based in the UK.

MIDS Cardiac™ is unique, because the technology is being developed to detect very low levels of cardiac markers to deliver accuracy that’s equal or superior to expensive state-of-the-art central laboratory analyzers, all while being accessible at the point of care and offering results within minutes.

The need for such reliable medical technology is growing in the U.S. and throughout the Western world. Anywhere from six to eight million Americans undertake an emergency hospital visit each year due to chest pain and suspected heart attacks. Cardiac diagnostic testing has become incredibly important, and the market niche has grown over the past few years. Currently, the value of the market is estimated between $2 billion and $6 billion in the U.S., as detailed in the Zacks article.

Standard procedure for chest pain patients is an immediate ECG, complemented by blood tests for the cardiac markers troponin I or T, to diagnose AMI. However, the sensitivity of an ECG is recognized as only around 55-75 percent accurate. Troponin proteins are associated with the cardiac muscle and they enter the bloodstream immediately after cardiac arrest. So far, high sensitivity troponin testing requires state-of-the-art laboratory analyzers, which are often unavailable and require at least an hour to turnaround results – a lengthy process that often includes repeated testing to rule out false positives.

Speedy diagnosis is of paramount importance for the treatment of people who have suffered heart attacks. Whenever the flow of blood to the heart is restricted after cardiac arrest, the muscle will begin to deteriorate. The process can be initiated in less than 30 minutes, which is why time is of the essence. Those who receive diagnosis and treatment within the so-called golden hour are more likely to recover without adverse side effects. If treatment does not occur within six hours, most of the heart will be injured beyond repair.

According to the American College of Cardiology and the American Heart Association, myocardial infarction blood tests should ideally be available within 30 minutes. The use of a device like MIDS Cardiac™ could help achieve this goal, as test results are available in a few minutes right at the point of care.

The successful development of MIDS Cardiac™ would be the first step in the development of a wider technology platform that could be adapted to a range of point of care immunoassay tests, based on the same concepts of speed, accuracy, ease of use and cost-effectiveness. Zenosense is planning to use the platform to develop a multi-capability point of care device that would test for different conditions, including prostate, colorectal and other cancers, inflammatory and autoimmune disease, osteoporosis, endocrine ailments, blood infections, respiratory viruses, meningitis, rheumatism, hepatitis, HIV, chlamydia and many more.

For more information, visit the company’s website at www.Zenosense.com

More from NetworkNewsWire

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.networknewswire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office


Select A Month

NetworkNewsWire Currently Accepts



Bitcoin Cash

Bitcoin Cash

Doge Coin






USD Coin

USD Coin

Contact us: 212.418.1217